DOCETAXEL NEAPOLIS 20 MG BT 1

Breast Cancer:

1- Doxetal (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer, in patients with lymph node invasion.

2- Doxetal (docetaxel) in combination with doxorubicin is indicated for the treatment of locally advanced or metastatic breast cancer in patients who have not received previous cytotoxic chemotherapy for this disease.

3- Doxetal (docetaxel) is indicated as monotherapy in the treatment of patients with locally advanced or metastatic breast cancer after failure of a cytotoxic chemotherapy regimen that included an anthracycline or an alkylating agent.

4- Doxetal (docetaxel) in combination with capecitabine is indicated for the treatment of locally advanced or metastatic breast cancer after a cytotoxic chemotherapy regimen that included an anthracycline.

Non-small Cell Lung Cancer:

1- Doxetal (docetaxel) is indicated for the treatment of locally advanced or metastatic non-small cell bronchial cancer, after failure of previous chemotherapy.

2- Doxetal (docetaxel) in combination with cisplatin is indicated for the treatment of unresectable, locally advanced or metastatic non-small cell bronchial cancer, in patients who have not received previous chemotherapy for this indication.

Prostate Cancer:

Doxetal (docetaxel) in combination with prednisone or prednisolone is indicated for the treatment of hormone-resistant metastatic prostate cancer.

Upper Aerodigestive Tract Cancers Doxetal (docetaxel), in combination with cisplatin and 5-Fluorouracil, is indicated for the induction treatment of locally advanced squamous cell carcinomas of the upper aerodigestive tract. -Gastric Cancer: Doxetal (docetaxel), in combination with cisplatin and 5-Fluorouracil, is indicated for the treatment of metastatic adenocarcinoma of the stomach, including adenocarcinoma of the oesophagogastric junction, in patients not previously treated with chemotherapy for their metastatic disease.